Auto-injector specialist Ypsomed is hopping on the United States manufacturing bandwagon, investing 200 million Swiss francs ($248 million) to build a plant in Holly Springs, North Carolina. It will be the first U.S. facility for the 41-year-old Swiss company.

Pelthos Therapeutics is seeking mothers who don’t mess around to raise awareness about the treatment of molluscum contagiosum.

AstraZeneca and Daiichi Sankyo are teeing up a TROP2 showdown with Gilead in first-line triple-negative breast cancer. China’s InnoCare agreed to out-license three autoimmune candidates to Zenas. Lupin plans to invest $250 million to build a new plant in Florida. And more.

The Senate has passed a new version of the Biosecure Act as part of an amendment to the National Defense Authorization Act for the upcoming fiscal year. While similar to last year’s edition, this amendment does not name prominent CDMOs WuXi Biologics and WuXi AppTec.

AstraZeneca has broken ground on a $4.5 billion manufacturing facility near Charlottesville, Virginia, confirming a report about its location six weeks ago when state lawmakers approved an economic development package for the project.

Pharma representatives who received an invite to the summit have reportedly expressed “consternation” over the concern that the event’s host and guest list imply that the White House wants drugmakers to work with BlinkRx.